Parnell Pharma Revenue, Profits - PARNF Annual Income Statement

Add to My Stocks
$0.15 $0.02 (15.38%) PARNF stock closing price Jun 22, 2018 (Closing)

Financial analysis of Parnell Pharma involves more than just checking the Parnell Pharma stock price, by looking at the financial statements of the company in detail. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 14.97M to 14.84M and how operating and non operating activities have impacted the PARNF stock. Revenue for year 2016 is $14.84M and has decreased from $14.97M year on year as is evident when you compare the latest figures in the latest Parnell Pharma profit and loss statement with those of the prior corresponding period. Also see Parnell Pharma assets and Parnell Pharma free cash flow for a complete valuation of PARNF stock.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Jan - Dec20162015201420132012
Parnell Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)6.67M5.83M-5.98M5.79M
Parnell Pharma Gross Profit
Research & Development Expense1.11M----
Selling General & Admin Expense20.34M17.85M-7.92M5.38M
Income Before Depreciation Depletion Amortization-13.28M-9.37M--5.32M-1.38M
Depreciation Depletion Amortization-----
Non Operating Income----8.06M-
Interest Expense2.84M---2.91M
Parnell Pharma Pretax Income
Provision for Income Taxes---2.78M-0.69M
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-16.13M-10.34M-12.94M-16.17M-3.57M
Extraordinary Items & Discontinued Operations-----
Parnell Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS15.83M13.33M10.87M7.56M-
Average Shares used to compute Basic EPS15.83M13.33M10.87M7.56M-
Income Before Nonrecurring Items-16.14M-9.89M-12.94M-3.57M-
Income from Nonrecurring Items-----
Parnell Pharma Earnings Per Share Basic Net
Parnell Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-1.02-0.74-1.19-0.47-
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.

It is very helpful to read a report on Parnell Pharma stock analysis. An investor must check the following items in an income statement:

  • Topline: A growing topline, as seen from the Parnell Pharma revenue chart, as isn't the case with Parnell Pharma indicates a sagging business. One needs to compare the YoY topline or sales growth of PARNF stock with its peers like SUWN stock and ACUR stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. PARNF stock had a poor bottom line growth.

The income statement is also called statement of revenue and expense. The PARNF financials along with Parnell Pharma historical stock prices provide a lot of details about the firm.

Parnell Pharma Income Statement - Key Financial Ratios